VXRT · Vaxart, Inc. · Investor Relations

Company to report third quarter 2026 financial results on November 5 SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today

Board-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQB: VXRT) (the “Company” or “Vaxart”), a clinical-stage biotechnology company

Second-generation oral mucosal vaccine candidate (VXA-H5-02) induced robust cross-neutralizing antibodies, significantly reduced viral load, and completely protected against lethal clade 2.3.4.4b viral challenge SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc.

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that a member of its management team will present at the

European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart’s Norovirus vaccine program through at least 2036 across key European markets KEY HIGHLIGHTS: • European Patent Office (EPO) granted Vaxart a new patent: European Patent No. 3791859.

Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main cohort anticipated in first half of 2027 Cash, cash equivalents, and investments of $64.0 million as of June 30,

Company to report second quarter 2026 financial results on August 6 SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today

SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in the

SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, yesterday held its Annual Meeting of

No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reported SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced topline data from the approximately 400-participant sentinel

Company to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees Stockholder Group Withdraws Director Nominations SOUTH SAN FRANCISCO, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc.

Details Strategic Actions Taken by the Board to Advance the Company’s Pipeline and Drive Value Creation Vaxart’s Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase of Growth Dissident Nominees Lack Relevant Clinical-Stage Biotech Expertise, Misrepresented Their

SOUTH SAN FRANCISCO, Calif., April 2, 2018 — Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the complete clinical dataset from the Phase 2 Challenge Study of its H1

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that Wouter Latour , M.D., president and chief executive officer of Vaxart , will

Issued Claims Cover High Yield Production Process of Phase 2 Antiviral SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT) a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will present clinical data from two Phase 1 studies of its

Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc. Combined Company Renamed Vaxart, Inc. and Will Begin Trading Under New Symbol NASDAQ: VXRT SOUTH SAN FRANCISCO, CA and ATLANTA, Feb. 13, 2018 — Vaxart, Inc. (NASDAQ: VXRT) today announced the completion of its merger with Aviragen

Vaxart Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study